Search
Trabectedin
go.drugbank.com/drugs/DB05109ApprovedInvestigationalTrabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. I...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesSQ-109
go.drugbank.com/drugs/DB05186InvestigationalSQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten th...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesHepatitis B immune globulin
go.drugbank.com/drugs/DB05276ApprovedInvestigationalLong-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. ...
Products: HEPATITIS B IMMUNOGLOBULIN P BEHRING, HEPATITIS B IMMUNOGLOBULIN P BEHRING 1000 IU/5 ML IM KULLANIMA HAZIR ENJEKTÖRDE ENJEKSİYONLUK ÇÖZELTİVandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalVandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectabl...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPalovarotene
go.drugbank.com/drugs/DB05467Approved[A244920] The ossification occurring as a result of FOP is insidious and cumulative and is provoked during flare-ups or in response to injury. … Treatment options for patients with FOP are extremely limited, although there has been substantial recent interest in novel treatments for this disease.
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesTelaprevir
go.drugbank.com/drugs/DB05521ApprovedWithdrawnTelaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsLaromustine
go.drugbank.com/drugs/DB05817InvestigationalVNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.
Categories: Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 SubstratesSar9, Met (O2)11-Substance P
go.drugbank.com/drugs/DB05875InvestigationalSar9, Met (O2)11-Substance P is a neurokinin-1 receptor agonist. … It is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species.
Synonyms: 9-Sar-substance P sulfone, 9-Sar-11-met(O2)-substance PKOS-1584
go.drugbank.com/drugs/DB05903InvestigationalKOS-1584 is a second-generation epothilone. Epothilones are anticancer agents with a taxane-like mechanism of action that have demonstrated activity in taxane-resistant tumors. KOS-1584 is a second-generation compound with increased pote...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsObeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigationalPrimary biliary cirrhosis, or PBC, is a progressive and chronic condition that leads to hepatic injury often resulting in end-stage liver failure that requires liver transplantation. Obeticholic acid is a farnesoid-X receptor (FXR) agoni...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors